Pharmaceutical firm Zydus Cadila Friday said it has received final approval from US health regulator to market lurasidone hydrochloride tablets used to treat mental disorders.
The approval by the US Food and Drug Administration (USFDA) for lurasidone hydrochloride tablets is for multiple strengths of 20 mg, 40 mg, 60 mg, 80 mg and 120 mg.
It will be manufactured at the group's manufacturing facility at SEZ, Ahmedabad, Cadila Healthcare, the listed entity of Zydus Cadila group, said in a regulatory filing.
The medication is used to treat certain mental/mood disorders such as schizophrenia, depression associated with bipolar disorder, it added.
The drug may also help to decrease hallucinations.
Zydus Cadila group now has 257 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY 2003-04, the filing said.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app